In one study, 18F-FDG PET had higher sensitivity (78%) and specificity (92%) than 123I-MIBG (50% and 75%, respectively) for detecting lesions in patients with MIBG-negative tumours or discordant imaging findings.109 However, 18F-FDG's use is limited by high physiological uptake in bone marrow and the brain, which can obscure small lesions and lead to false positives, especially after chemotherapy or G-CSF treatment.110–112 [68Ga]Ga-DOTATATE PET-CT, which targets somatostatin receptors (primarily SSTR2), has also demonstrated excellent performance. This evidence concerns the gene SSTR2 and neoplasm.